Table 1.
Summary of the salient therapeutic and outcome data of the reported cases of adamantinoma-like Ewing sarcoma of the thyroid
| Reference | Age/sex | Fusion | Surgery/adjuvant treatment | Follow up/outcome | LN metastasis | Distant metastasis |
|---|---|---|---|---|---|---|
| Cruz et al. and Eloy et al.^ [6, 7] | 42/F | EWSR1-FLI1 | TT/none | 38 months/ANED | N | N |
| Eloy et al.^ [8] | 24/M | EWSR1-FLI1 | TT/RAI/ESP | 13 years/ANED | N | N |
| Bishop et al. [1] | 19/M | EWSR1-FLI1 | TT/unknown | n/a | n/a | n/a |
| Bishop et al. [1] | 36/F | EWSR1-FLI1 | TT/unknown | n/a | n/a | n/a |
| Ongkeko et al. [9] | 36/M | EWSR1-FLI1 | TT/Radiation after initial diagnosis of PDTC; chemotherapy | 2 years/alive, restaging PET showed complete response | Y | Y (pancreas) |
| Current case | 20/F | EWSR1-FLI1 | TT/ESP/radiation | 7 months/ANED; PET scan NED at 7 months | N | N |
n/a not available, N no, Y yes, TT total thyroidectomy, RAI radioactive iodine, ESP Ewing sarcoma therapy protocol, ANED alive no evidence of disease, PDTC poorly differentiated thyroid carcinoma
^Reported under the name “carcinoma of the thyroid with Ewing family tumor elements”